An interventional study of Insulin Balance Formula - Hormetics Weight Optimization System in Insulin, sponsored by Efforia, Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Efforia, Inc · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,118 studies in Insulin Resistance with a site in United States — 117 open to participants now, 149 under way, 2 of them phase 3. Insulin Resistance · United States.
Among the 1,118 studies in Insulin Resistance with a site in United States, this one is the 158th largest by planned enrollment of the 936 interventional ones that give a count, is one of 28 that started in 2025, is one of 535 with no phase, reaches primary completion later than 30 of the 146 other live ones, and was the 1,087th registered.
2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.
Browse Insulin Resistance studies →117 of the 1,118 studies in Insulin Resistance with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–100
HealthPartners Institute · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
University of Colorado, Denver · Sites in United States
Ages 14–19
St. Louis University · Sites in United States
Ages 18–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 137 · Phase 2 162 · Phase 3 45 · Phase 4 100
First in 1976; this study’s year is marked. 28 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 2,371 interventional studies indexed under Insulin Resistance.
Median enrollment 37 across the 936 interventional studies, 48 across the 174 observational. Of the 872 that completed or were terminated, 311 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 1,118 have an industry lead sponsor. The 10 most frequent:
Efforia, Inc is the lead sponsor of 25 studies on the registry; 20 are open to participants now.
Efforia, Inc has 1 study filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
53 of the studies in Insulin Resistance with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03947697University of Texas, El PasoImproving Glycemic Control With Electrical Stimulation | 2026-11-25 |
| NCT05958368Pennington Biomedical Research CenterAssessing the Value of Avocados on Glycemic Control in Type 2 Diabetes | 2026-11-30 |
| NCT05441982Virginia Polytechnic Institute and State UniversitySaccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes | 2026-11-30 |
| NCT03318094Vanderbilt University Medical CenterRole of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity | 2026-11-30 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
Add all 53 to your calendar (.ics) → With an account.
Among the 1,118 studies in Insulin Resistance with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Explore how a dietary supplement can help support healthy insulin levels and its impact on weight, fatigue, and sugar cravings. The Insulin Balance Formula and Hormetics Weight Optimization System is designed for people who are generally healthy and want to support and maintain healthy insulin levels to reach general health goals.
Treatment activities:
Daily Activity: Take 3 capsules of the Insulin Balance Supplement daily, ideally 1 capsule before each meal or all at once for convenience. Begin with 1 capsule to assess tolerance and increase to the recommended dose. Take on an empty stomach or with a meal if needed.
Assessments and frequency:
Body Composition Measurement: Complete the assessment as required. PROMIS Sleep Disturbance Scale: Complete the assessment as required. Carbohydrate Craving Questionnaire: Complete the assessment as required. After Meal Hunger \& Fatigue Perception: Complete the assessment as required.
Methodology:
The "Insulin Balance Metabolic Health and Weight Optimization Protocol" is an observational study designed to investigate the effects of a dietary supplement on insulin levels and its subsequent impact on weight management, fatigue, and sugar cravings. In this study, participants serve as their own controls in a single-arm design, a scientific approach known as the "Signal Phase" at Efforia. This trial aims to detect initial positive outcomes that suggest the supplement's effectiveness in promoting metabolic health. During this phase, not only will potential benefits be identified, but it will also gather critical safety data that is currently limited, thereby paving the way for more comprehensive studies in the future.
Participants will partake in a 30-day structured protocol, during which they will incorporate the Insulin Balance Formula into their daily routines alongside a balanced diet. The study is crucial because it addresses the challenges many face in maintaining stable insulin and blood sugar levels, which are essential for metabolic health. By closely monitoring their response to the supplement, participants will provide valuable insights into how this nutritional strategy may enhance energy levels, improve mood consistency, and support healthy weight maintenance. Their role is pivotal in assessing the formula's impact under real-world conditions, generating meaningful data that can inform future interventions.
Throughout the study, participants are encouraged to actively engage and provide honest feedback, ensuring accurate, personalized results. The study emphasizes the importance of privacy and data confidentiality, assuring participants that their information will only be used within the research context. Participants are also advised against introducing new supplements or health interventions during the trial to avoid confounding results. Should any health concerns arise, they are instructed to seek medical attention immediately. The insights gained from this study could significantly advance understanding of nutritional support for managing blood sugar levels, potentially leading to more robust research designs if positive signals are detected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single Arm longitudinal where participants act as their own control
Dietary Supplement: Insulin Balance Formula - Hormetics Weight Optimization System
The Insulin Balance Formula, doctor-formulated by Dr. Miriam Mikicki, MD, and Elwin Robinson, combines five potent ingredients, each chosen for its proven ability to combat insulin resistance and support weight loss. Sourced from premium suppliers, these ingredients blend ancient wisdom with modern science: Berberine 500mg Beta Alanine 500 mg Zinc Citrate 15 mg Folate 200 mcg Fenugreek Extract 500 mg
Waist Circumference Measured by Flexible Tape Measure
Waist circumference will be measured in centimeters (cm) using a non-elastic, flexible anthropometric tape measure. Measurements will be taken at the midpoint between the lowest rib and the iliac crest with the participant standing, at the end of a normal exhalation. Two measurements will be obtained, and the average value will be recorded.
Time frame: Assessed at baseline prior to intervention initiation (Day 0) and at study completion (Day 30)
PROMIS Sleep Disturbance Scale
Measurement Scale: The PROMIS Sleep Disturbance Scale is a standardized, participant-reported questionnaire consisting of multiple items rated on a 5-point Likert scale (typically ranging from 1 = "Not at all" to 5 = "Very much"). Item responses are summed and converted to a T-score standardized to the general population (mean = 50, standard deviation = 10). Score Interpretation: Higher scores indicate greater sleep disturbance (worse sleep quality), while lower scores indicate better sleep quality.
Time frame: Assessed at baseline prior to intervention initiation (Day 0) and at study completion (Day 30)
Carbohydrate Craving Questionnaire
Measurement Scale: The Carbohydrate Craving Questionnaire (CCQ) is a validated, participant-reported questionnaire designed to assess the frequency and intensity of carbohydrate-related cravings. Items are rated on a Likert-type scale (typically ranging from 1 = "Strongly disagree" to 6 or 7 = "Strongly agree," depending on the CCQ version). Item responses are summed to generate a total score. Score Interpretation: Higher total scores indicate greater carbohydrate craving severity, while lower scores indicate lower levels of carbohydrate craving.
Time frame: Assessed at baseline prior to intervention initiation (Day 0) and at study completion (Day 30)
After Meal Hunger & Fatigue Perception
This survey aims to understand how individuals perceive different stages of hunger and fatigue after their most recent meal. The respondents are required to select the option that best describes their current state of hunger or fullness, based on a scale of 1 through 10, with 10 being the most favorable. In addition, this survey measures current state of hunger-associated fatigue from "very drowsy" to "very alert" with "very alert" being the most favorable.
Time frame: Assessed at baseline prior to intervention initiation (Day 0) and at study completion (Day 30), along with random repetitions 6 times per 2 weeks throughout study.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.
Of 40 industry-sponsored interventional studies with no phase under Insulin Resistance, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 22. This study's planned 12 months is above that.
Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.